COPD, Small Airway Disease
Conditions
Keywords
COPD, Small Airway Dysfunction, Impulse oscillometry
Brief summary
Chronic obstructive pulmonary disease (COPD) is a worldwide prevalent disease. During recent years, increasing attention has been directed to the importance of the contribution of small airways in respiratory diseases. The small airways (usually defined as those with an internal diameter of \<2 mm) are recognized as the major site of resistance to airflow in obstructive lung disease. Although small airway disease is known in chronic airway diseases, the importance of small airway dysfunction on disease control, exacerbations and quality of life, and the importance of taking place among treatable targets is not clear. Therefore, our aim in the study is to determine the frequency of small airway dysfunction in COPD. Our secondary aim is to evaluate the role of small airway dysfunction in disease severity, disease phenotypes, disease control, quality of life and its effect on predicting the risk of exacerbation and its role among treatable targets in chronic airway diseases.
Detailed description
This is a prospective cross-sectional interventional design. 100 COPD patients who applied to Mersin University Faculty of Medicine Hospital Chest Diseases Clinic between 01.10.2019-01.04.2020 will be taken. 35 healthy participants with smoking history and 35 healthy participants without smoking history who were admitted to our clinic within the same date range will be taken as control group. Impulse oscillometric pulmonary function tests will be performed to all participants. Thorax computed tomography will be performed to evaluate small airway dysfunction. To evaluate the degree of disease inflammation and phenotype in COPD patients, nitric oxide measurements will be made in the breath air with fractional exhaled nitric oxide (FENO) device. The blood eosinophil level will be studied to determine the COPD phenotype. To assess symptom control in patients with COPD, mMRC(Modified Medical Research Council) dyspnea scale will be administered. The COPD assessment test (CAT) will be applied to measure the quality of life. All patients will be followed for 1 year to record the number of exacerbations requiring emergency and hospital admissions for COPD. The effect of small airway dysfunction on the disease severity and control degree, disease phenotypes and quality of life, and the effect on the risk of exacerbation will be analyzed.
Interventions
DIAGNOSTIC_TESTImpulse oscillometry
Impulse oscillometry is a pulmonary function test. During the test, the participant is told to breathe normally.
DIAGNOSTIC_TESTSpirometric pulmonary function test
In the spirometric pulmonary function test, the participant is asked to perform respiratory maneuvers such as breathing deeply.
DIAGNOSTIC_TESTFractional exhaled nitric oxide (FENO) test
In the FENO test, the participant is asked to perform respiratory maneuvers such as breathing deeply.
DIAGNOSTIC_TESTThorax Computed Tomography
Computed tomography is a radiological examination.
DIAGNOSTIC_TESTChest X Ray
Chest X ray is a radiological examination.
DIAGNOSTIC_TESTBlood eosinophil level
A tube of blood will be drawn from the participant.
OTHERCAT
It consists of 8 questions.
OTHERmMRC
It is the scale used to measure the severity of shortness of breath.
Sponsors
Mersin University
Sibel Naycı
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
COPD group * Participants who applied to the chest diseases clinic of Mersin University Hospital, between October 1, 2019 and April 1, 2020 * Participants who were diagnosed COPD with spirometry test * Reading and signing Informed Consent Form * Participants must be older than 18 years Healthy control group with a history of smoking * To apply to the chest diseases clinic of Mersin University Hospital between October 1, 2019 and April 1, 2020 * Reading and signing informed consent form * Participants must be older than 18 years * Must have no lung disease * Must have 10 packs / year or more than 10 packs / year smoking history Healthy control group without smoking history * To apply to the chest diseases clinic of Mersin University Hospital between October 1, 2019 and April 1, 2020 * Reading and signing informed consent form * Participants must be older than 18 years * Must have no lung disease * Must have no smoking history
Exclusion criteria
* Participants who do not sign the Informed Consent Form * Under the age of 18 years * Pregnant women * Participants who with a history of cancer in the past 5 years * Participants who previously had lung surgery * Participants who with Interstitial Lung Disease * Participants who with respiratory muscle disease * Participants who with active pulmonary tuberculosis * Participants who can not perform respiratory function tests
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Forced expiratory volume in 1 second (fev1) change will be evaluated by spirometric pulmonary function test. | through study completion, an average of 1 year | Forced expiratory volume in 1 second (fev1) change over one year period will be evaluated with spirometric pulmonary function test during recruitment and 1st year of follow-up. |
| Small airway dysfunction will be evaluated by body plethysmography test. | through study completion, an average of 1 year | Residual volume (RV) and total lung capacity (TLC) will be measured by body plethysmography test to determine small airway dysfunction. |
| Symptoms will be evaluated by Modified Medical Research Council Dyspnea Scale (mMRC). | through study completion, an average of 1 year | The mMRC (Modified Medical Research Council) scale is a self-rating tool to measure the degree of disability that breathlessness poses on day-to-day activities on a scale from 0 to 4: 0, no breathlessness except on strenuous exercise; 1, shortness of breath when hurrying on the level or walking up a slight hill; 2, walks slower than people of same age on the level because of breathlessness or has to stop to catch breath when walking at their own pace on the level; 3, stops for breath after walking ∼100 m or after few minutes on the level; and 4, too breathless to leave the house, or breathless when dressing or undressing. |
| The number of moderate and severe exacerbations over a 1 year period will be recorded. | through study completion, an average of 1 year | In the COPD group, each participant will be followed for 1 year in terms of recording exacerbations. |
| Small airway dysfunction will be evaluated by performing impulse oscillometry test. | through study completion, an average of 1 year | Respiratory resistance at 5 and 20 Hz (R5 and R20, respectively) will be used for the analyses. R5 and R20 are regarded as reflecting total and proximal airway resistance, respectively, and the fall in resistance from R5 to R20 (R5-R20) will used as a surrogate for the resistance of small airways. |
| Small airway dysfunction will be evaluated by thorax computed tomography. | through study completion, an average of 1 year | Indirect changes caused by the small airways on the lung parenchyma will be detected by computed tomography (CT). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Complete blood count ( CBC) test will be used as an indicator of inflammation. | through study completion, an average of 1 year | Blood eosinophil levels will be recorded. |
| Quality of life will be evaluated by COPD Assessment Test (CAT). | through study completion, an average of 1 year | COPD Assessment Test (CAT) contains 8 questions. In each question, the minimum value is zero and the maximum value is five points. Higher score means worse outcome. |
| Fractional Exhaled Nitric Oxide (FENO) test will be used as an indicator of inflammation. | through study completion, an average of 1 year | FENO test is indirect measurements of inflammation, as used in clinical practice. |
Countries
Turkey (Türkiye)
Outcome results
None listed